



Grant of Options

July 12, 2022

RNS Number : 0898S

MaxCyte, Inc.

12 July 2022

MaxCyte, Inc.
("MaxCyte" or the "Company")

Grant of Options

Gaithersburg, Maryland - 12 July 2022: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), the global clinical-stage cell-based therapies and life sciences company, announces that on 29 June 2022, a total of 188,300 options of common stock in the Company ("Common Stock") were granted to PDMRs who are non-executive directors of the Company. These annual option grants were made pursuant to the Company's Equity Grant Policy for non-executive directors ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs	
Al-Wakeel, Yasir	26,900
Brooke, Will	26,900
Douglas, Richard	26,900
Erck, Stanley	26,900
Hemrajani, Rekha	26,900
Johnston, John	26,900
Mandell, Art	26,900
Total	188,300

Option Grants for non-executive directors fully vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).

The Options Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 29 June 2022, of 410 pence.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	a) Yasir Al-Wakeel b) Will Brooke c) Richard Douglas d) Stanley Erck e) Rekha Hemrajani f) John Johnston

		g) Art Mandell																
2	Reason for the notification																	
a)	Position/status	a) Non-Executive Director b) Non-Executive Director c) Non-Executive Chairman d) Non-Executive Director e) Non-Executive Director f) Non-Executive Director g) Non-Executive Director																
b)	Initial notification /Amendment	Initial notification																
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor																	
a)	Name	MaxCyte Inc.																
b)	LEI	54930053YHXULRFCU991																
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted																	
a)	Description of the financial instrument, type of instrument Identification code	Common Stock of \$0.01 each US57777K1060																
b)	Nature of the transaction	Grant of options of common stock																
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) £4.10</td> <td>26,900</td> </tr> <tr> <td>b) £4.10</td> <td>26,900</td> </tr> <tr> <td>c) £4.10</td> <td>26,900</td> </tr> <tr> <td>d) £4.10</td> <td>26,900</td> </tr> <tr> <td>e) £4.10</td> <td>26,900</td> </tr> <tr> <td>f) £4.10</td> <td>26,900</td> </tr> <tr> <td>g) £4.10</td> <td>26,900</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	a) £4.10	26,900	b) £4.10	26,900	c) £4.10	26,900	d) £4.10	26,900	e) £4.10	26,900	f) £4.10	26,900	g) £4.10	26,900
Exercise Price(s)	Volume(s)																	
a) £4.10	26,900																	
b) £4.10	26,900																	
c) £4.10	26,900																	
d) £4.10	26,900																	
e) £4.10	26,900																	
f) £4.10	26,900																	
g) £4.10	26,900																	
d)	Aggregated information - Aggregated volume - Price	188,300 £4.10																
e)	Date of the transaction	29 June 2022																
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)																

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

Nominated Adviser and Joint

Corporate Broker

+44 (0)20 7886 2500

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

UK IR Adviser

+44 (0)203 709 5700

Consilium Strategic

maxcyte@consilium-comms.com

Communications

Mary-Jane Elliott

Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHRBMLTMTBBBT